This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Wendy S. Johnson net worth and biography

Wendy Johnson Biography and Net Worth

Director of Exagen

Ms. Johnson has a distinguished career in healthcare performing various roles integral to corporate growth. She is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company’s UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014. Prior to joining ProQuest, she held senior business and corporate development positions at Salmedix Inc., WomenFirst Healthcare, Prizm Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson is also presently on the Board of Directors of MorphoSys AG, one of the oldest biotechnology companies in Europe. Ms. Johnson received an M.B.A. from Loyola University Maryland, her M.S. in Clinical Microbiology from the Hahnemann Medical School, and her B.S. in Microbiology from the University of Maryland.

What is Wendy S. Johnson's net worth?: The estimated net worth of Wendy S. Johnson is at least $4,100.00 as of October 5th, 2015. Dr. Johnson owns 1,000 shares of Exagen stock worth more than $4,100 as of November 23rd. This net worth estimate does not reflect any other investments that Dr. Johnson may own. Learn More about Wendy S. Johnson's net worth.
How do I contact Wendy S. Johnson?: The corporate mailing address for Dr. Johnson and other Exagen executives is 1261 Liberty Way Suite C, VISTA CA, 92081. Exagen can also be reached via phone at 760-560-1501 and via email at [email protected]. Learn More on Wendy S. Johnson's contact information.
Has Wendy S. Johnson been buying or selling shares of Exagen?: Wendy S. Johnson has not been actively trading shares of Exagen within the last three months. Learn More on Wendy S. Johnson's trading history.
Who are Exagen's active insiders?: Exagen's insider roster includes Wendy Johnson (Director), and James Tullis (Director). Learn More on Exagen's active insiders.
Are insiders buying or selling shares of Exagen?: In the last year, Exagen insiders bought shares 2 times. They purchased a total of 64,706 shares worth more than $145,866.97. In the last year, insiders at the sold shares 1 times. They sold a total of 12,784 shares worth more than $24,417.44. The most recent insider tranaction occured on November, 14th when CEO John Aballi bought 24,305 shares worth more than $68,297.05. Insiders at Exagen own 26.1% of the company. Learn More about insider trades at Exagen.
Information on this page was last updated on 11/14/2024.

Wendy S. Johnson Insider Trading History at Exagen

Wendy S. Johnson Buying and Selling Activity at Exagen

Exagen Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Today's Range

Now: $4.10

$3.91

$4.42

50 Day Range

MA: $2.89

$2.43

$4.20

2 Week Range

Now: $4.10

$1.30

$4.83

Volume

119,675 shs

Average Volume

46,163 shs

Market Capitalization

$72.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad